Last reviewed · How we verify
intermediate dose Enoxaparin/ unfractionated heparin
Enoxaparin and unfractionated heparin work by inhibiting the coagulation cascade, specifically by activating antithrombin and inhibiting thrombin and factor Xa.
Enoxaparin and unfractionated heparin work by inhibiting the coagulation cascade, specifically by activating antithrombin and inhibiting thrombin and factor Xa. Used for Prophylaxis and treatment of deep vein thrombosis and pulmonary embolism, Atrial fibrillation for stroke prevention.
At a glance
| Generic name | intermediate dose Enoxaparin/ unfractionated heparin |
|---|---|
| Also known as | Intermediate dose anticoagulation |
| Sponsor | Rajaie Cardiovascular Medical and Research Center |
| Drug class | Low molecular weight heparin |
| Target | Antithrombin |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This leads to a decrease in the formation of blood clots and an increase in the breakdown of existing clots. Enoxaparin and unfractionated heparin are both anticoagulants that are used to prevent and treat deep vein thrombosis and pulmonary embolism.
Approved indications
- Prophylaxis and treatment of deep vein thrombosis and pulmonary embolism
- Atrial fibrillation for stroke prevention
Common side effects
- Hemorrhage
- Thrombocytopenia
- Osteoporosis
Key clinical trials
- A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants (PHASE1)
- AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia (PHASE3)
- Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk (PHASE4)
- Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19 (PHASE4)
- Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients (PHASE2)
- Anti-Xa Guided Dosing of Low Molecular Weight Heparin for Prevention of Venous Thromboembolism Following Traumatic Injury: a Multicentre Pilot Randomized Trial (PHASE2, PHASE3)
- Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial (PHASE3)
- Prolonged Hypercoagulability Following Major Liver Resection for Malignancy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: